BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Omvoh (mirikizumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Omvoh (mirikizumab)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07446101-4@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Omvoh (mirikizumab): Phase 1 readout est. (NCT07446101)
DESCRIPTION:Omvoh (mirikizumab)\, phase 1.\nStudy: A Study of Mirikizumab S
 olution (LY3074828) in Healthy Participants\nEstimated primary completion:
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mirik
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07446101
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07186101-4@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Omvoh (mirikizumab): Phase 2 readout est. (NCT07186101)
DESCRIPTION:Omvoh (mirikizumab)\, phase 2\, Ulcerative Colitis.\nStudy: LY4
 268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderate
 ly to Severely Active Ulcerative Colitis:\nEstimated primary completion: M
 ay 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/mirikizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0718
 6101
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997965-4@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Omvoh (mirikizumab): Phase 4 readout est. (NCT06997965)
DESCRIPTION:Omvoh (mirikizumab)\, phase 4\, Crohn's Disease.\nStudy: Open-l
 abel Single-arm Study to Assess the Efficacy of Mirikizumab in Patients Wi
 th Inflammatory Strictures Due to CD\nEstimated primary completion: 1 Sept
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mirikizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6997965
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06864403-4@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Omvoh (mirikizumab): Phase 4 readout est. (NCT06864403)
DESCRIPTION:Omvoh (mirikizumab)\, phase 4.\nStudy: Mirikizumab in the Treat
 ment of Chronic Inflammatory Conditions of the Pouch\nEstimated primary co
 mpletion: October 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/mirikizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06864403
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07292012-4@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Omvoh (mirikizumab): Phase 4 readout est. (NCT07292012)
DESCRIPTION:Omvoh (mirikizumab)\, phase 4\, Crohn's Disease.\nStudy: Effica
 cy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's D
 isease\nEstimated primary completion: November 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/mirikizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07292012
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05509777-4@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Omvoh (mirikizumab): Phase 3 readout est. (NCT05509777)
DESCRIPTION:Omvoh (mirikizumab)\, phase 3\, Crohn's Disease.\nStudy: A Stud
 y of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Diseas
 e\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/mirikizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05509777
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235904-4@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Omvoh (mirikizumab): Phase 4 readout est. (NCT07235904)
DESCRIPTION:Omvoh (mirikizumab)\, phase 4\, Ulcerative Colitis.\nStudy: Eff
 icacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Az
 athioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative 
 Colitis\nEstimated primary completion: March 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/mirikizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07235904
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937086-4@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Omvoh (mirikizumab): Phase 3 readout est. (NCT06937086)
DESCRIPTION:Omvoh (mirikizumab)\, phase 3\, Ulcerative Colitis.\nStudy: Mir
 ikizumab Administered at the Same Time as Tirzepatide in Adult Participant
 s With Moderately to Severely Active Ulcerative Colitis and Obesity or Ove
 rweight: Phase 3b Study\nEstimated primary completion: April 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/mirikizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06937086
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937099-4@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Omvoh (mirikizumab): Phase 3 readout est. (NCT06937099)
DESCRIPTION:Omvoh (mirikizumab)\, phase 3\, Crohn's Disease.\nStudy: Miriki
 zumab and Tirzepatide Administered in Adult Participants With Moderately t
 o Severely Active Crohn's Disease and Obesity or Overweight\nEstimated pri
 mary completion: May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/mirikizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06937099
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686757-4@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Omvoh (mirikizumab): Phase 4 readout est. (NCT07686757)
DESCRIPTION:Omvoh (mirikizumab)\, phase 4\, Ulcerative Colitis.\nStudy: INS
 IGHT-IBD Pragmatic Study\nEstimated primary completion: June 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/mirikizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07686757
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612267-4@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Omvoh (mirikizumab): Phase 4 readout est. (NCT07612267)
DESCRIPTION:Omvoh (mirikizumab)\, phase 4\, Ulcerative Colitis.\nStudy: A S
 tudy to Measure Mirikizumab Levels in Breast Milk of Lactating Participant
 s Receiving Mirikizumab Therapeutically for an Approved Indication\nEstima
 ted primary completion: September 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/mirikizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07612267
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07782021-4@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Omvoh (mirikizumab): Phase 4 readout est. (NCT07782021)
DESCRIPTION:Omvoh (mirikizumab)\, phase 4\, Crohn's Disease.\nStudy: MIRICU
 RE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizi
 ng Crohn's Disease\nEstimated primary completion: December 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/mirikizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07782021
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07659353-4@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Omvoh (mirikizumab): Phase 4 readout est. (NCT07659353)
DESCRIPTION:Omvoh (mirikizumab)\, phase 4\, Crohn's Disease.\nStudy: Effica
 cy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azath
 ioprine in Patients With Newly Diagnosed\, Moderate-to-severe Crohn's Dise
 ase\nEstimated primary completion: 31 March 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/mirikizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07659353
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04844606-4@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Omvoh (mirikizumab): Phase 3 readout est. (NCT04844606)
DESCRIPTION:Omvoh (mirikizumab)\, phase 3\, Ulcerative Colitis.\nStudy: A M
 aster Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Par
 ticipants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)\nEstimated
  primary completion: December 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/mirikizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04844606
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
